Business
Novonesis delivered strong organic sales growth of 7% in 2025
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong perfor
About this update from Novonesis A/s Class B
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: Highlights of our full-year 2025 results: • Broad-based organic sales growth of 7% (Q4: 4%) including the negative impact of exiting certain countries of ~1%-point (Q4: ~2%-points). Price contributed ~1%-point (Q4: ~1%-point) and sales synergies contributed ~1%-point (Q4: ~1%-point). • Food & Health at 8% organic sales growth (Q4: 7%) including the negative impact of exiting certain countries of ~3%-points (Q4: ~5%- points). Planetary Health at 6% organic sales growth (Q4: 2%, including double-digit growth in Energy). • Emerging Markets grew 9% organically (Q4: 1%) including the exit from certain countries. Developed Markets grew 6% organically (Q4: 6%). • Adjusted EBITDA margin at 37.1% (Q4: 36.6%), up by 100 bps (Q4: up by 40 bps) including one-off expenses in Q4 and currency headwinds for both the quarter and the year. Adjusted gross margin at 59.1% (Q4: 59.9%) up by 240bps (Q4: up by 250bps). • Adjusted net profit increased by 17% (Q4: flat). • NIBD/EBITDA at 1.9x, and free cash flow before acquisitions at EUR 770.4 million, or 19% of sales. • Proposed dividend of DKK 4.25/share. DKK 2.25/share interim dividend paid Aug. 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit. • 33 new product launches in 2025 (Q4: 14). New innovations launched over the last 5 years made up 25% of sales. • Achievement of all six environmental and social targets for 2025 and on track for future commitments. • 2026 outlook: Organic sales growth between 5-7% with a good start to the year expected against a strong 2025 comparable. The outlook includes some uncertainty of potential lower consumer sentiment for the year. The outlook also includes ~1%-point from positive pricing and ~1%-point from sales synergies as well as close to 1%-point negative impact from exiting certain countries. The outlook for the adjusted EBITDA margin is between 37-38% with an expected margin expansion, including currency headwinds of ~50 bps vs 2025. Here is the link to the investor call on Novonesis full-year results for 2025: Novonesis Full-year financial statement for 2025 and annual report 2025 Get in touch Line Fedders Senior Media Relation Manager [email protected] +45 30 77 13 99 Tobias Bjorklund Head of Investor Relations [email protected] Attachment
View stock analysis, news, and events for Novonesis A/s Class B